摘要
目的 评价多西他赛/米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌的临床效果.方法 选取我院2010年3月～2015年5月收治的80例激素抵抗性前列腺癌患者作为研究对象,随机分为对照组和观察组,每组40例.观察组采用米托蒽醌联合泼尼松治疗,对照组采用多西他赛联合泼尼松治疗进行治疗,观察两组患者治疗的总有效率和不良反应发生率.结果 两组患者治疗的总有效率相近,观察组的不良反应发生率优于对照组,P＜0.05,差异具有统计学意义.结论 米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌的临床效果显著,可有效降低并发症发生率.
Objective Evaluate docetaxel / mitoxantrone combined with prednisone clinical effects of hormone-resistant prostate cancer.Methods Selected 80 cases of hormone-resistant prostate cancer patients from March 2010 to May 2015 in our hospital as research subjects, were randomly divided into the control group and the observation group, each group had 40 cases. The observation group with mitoxantrone and prednisone therapy, the control group with docetaxel for treatment, and patients were observed for total efficiency and incidence of adverse reactions.Results After this research, two groups of patients had similar overall efficiency, but the incidence of adverse reactions observation group than the control group,P〈0.05, was difference had statistically significance.Conclusion Mitoxantrone combine with prednisone in the treatment of hormone-resistant prostate cancer has good clinical effect, which could effectively reduce the incidence of complications.
出处
《中国继续医学教育》
2015年第31期182-183,共2页
China Continuing Medical Education
